Related Experiment Video
Updated: Mar 14, 2026
Gene Transfer for Ischemic Heart Failure in a Preclinical Model
Published on: May 15, 2011
Influenza vaccine as a coronary intervention for prevention of myocardial infarction
C Raina MacIntyre1,2, Abela Mahimbo1, Aye M Moa1
1School of Public Health and Community Medicine, University of New South Wales, Sydney, Australia.
Insights
Influenza vaccination significantly protects against heart attacks, offering benefits comparable to other cardiovascular disease prevention methods. Increased vaccination rates are crucial for managing and preventing cardiovascular events.
Area of Science:
- Cardiology
- Infectious Diseases
- Public Health
Background:
- Cardiovascular disease (CVD) is a primary global cause of death.
- Influenza infection can trigger acute myocardial infarction (AMI) through inflammation and thrombogenesis.
- Existing evidence links influenza to cardiovascular events.
Purpose of the Study:
- To evaluate the efficacy of influenza vaccination in preventing AMI.
- To compare influenza vaccine efficacy with established CVD prevention strategies.
- To advocate for integrating influenza vaccination into routine CVD care.
Main Methods:
- Review of observational studies and clinical trials on influenza vaccination and AMI.
- Analysis of vaccine efficacy estimates.
- Comparison with efficacy data for smoking cessation, statins, and antihypertensive therapy.
Main Results:
- Influenza vaccination demonstrates efficacy in preventing AMI, with estimates ranging from 15% to 45%.
- This efficacy is comparable to that of smoking cessation, statins, and antihypertensive therapies.
- Vaccination rates in at-risk populations under 65 remain low (around 30%).
Conclusions:
- Influenza vaccination is a vital component of cardiovascular disease management and prevention.
- Despite recommendations, uptake in at-risk groups is insufficient.
- A paradigm shift in clinical practice is needed to incorporate vaccination into routine CVD care.
Abstract:
Cardiovascular disease (CVD) is the leading cause of morbidity and mortality globally. Influenza is one of the leading infectious causes of morbidity and mortality globally, and evidence is accumulating that it can precipitate acute myocardial infarction (AMI). This is thought to be due to a range of factors including inflammatory release of cytokines, disruption of atherosclerotic plaques and thrombogenesis, which may acutely occlude a coronary artery. There is a large body of observational and clinical trial evidence that shows that influenza vaccine protects against AMI. Estimates of the efficacy of influenza vaccine in preventing AMI range from 15% to 45%. This is a similar range of efficacy compared with the accepted routine coronary prevention measures such as smoking cessation (32-43%), statins (19-30%) and antihypertensive therapy (17-25%). Influenza vaccine should be considered as an integral part of CVD management and prevention. While it is recommended in many guidelines for patients with CVD, rates of vaccination in risk groups aged <65 years are very low, in the range of 30%. The incorporation of vaccination into routine CVD prevention in patient care requires a clinical practice paradigm change.
More Related Videos
Related Concept Videos
01:26Coronary Artery Disease IV: Preventive Measures
01:14Myocarditis III: Medical Management
01:26Angina IV: Management
01:17Ischemic Heart Disease: Overview
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
01:21Rheumatic Heart Disease III: Medical Management
01:30Coronary Artery Disease I: Introduction